×
0 0 0 0 0 0 0 0
Stockreport

Lilly breast cancer drug wins expanded U.S. approval [Reuters]

ELI LILLY (LLY)  More Company Research Source: Reuters
Last eli lilly earnings: 7/24 06:25 am Check Earnings Report
US:NYSE Investor Relations: investor.lilly.com
PDF Lilly breast cancer drug wins expanded U.S. approval | Reuters Reuters Staff 2 Min Read (Reuters) - U.S. regulators have approved expanded use of Eli Lilly and Co’s Verzenio breast cancer drug as an initial treatment for certain women with advanced or metastatic disease, a decision that should boost sales of the medicine, the company said on Monday. The Food and Drug Administration approved the drug in combination with an aromatase inhibitor in previously untreated postmenopausal women with HR positive, HER2-negative advanced breast cancer. Verzenio was originally approved last September in combination with AstraZeneca’s Faslodex (fulvestrant) once the disease had progressed following endocrine therapy. The Lilly oral drug competes with Pfizer’s Ibrance and Kisqali from Novartis. The expanded approval was based on a late-stage study in which Verzenio, known chemically as abemaciclib, taken twice a day with either anastrozole or letrozole significantly delayed disease progression compa [Read more]

IMPACT SNAPSHOT EVENT TIME: LLY
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
LLY alerts

from News Quantified
Opt-in for
LLY alerts

from News Quantified